Gender Disparity and Temporal Trend of Liver Cancer in China from 1990 to 2019 and Predictions in a 25-year Period

Overview

Journal Front Public Health

Specialty Public Health

Date 2022 Sep 12

PMID 36091549

Authors

Tingting Yue

Ming Xu

Ting Cai

Haizhen Zhu

Mahmoud Reza Pourkarim

Erik De Clercq

Guangdi Li

Affiliations

Soon will be listed here.

Abstract

Objective: This study aims to reveal epidemiological features and trends of liver cancer (LC) in China.

Methods: We retrieved data from the Global Burden of Disease database 2019. Joinpoint regression was used to examine the temporal trend of LC. Future trends of LC were estimated using the Nordpred.

Results: The incidence, mortality, and disability-standardized life year (DALY) rate of LC declined in China from 1990 to 2019. Among >210,000 LC cases in 2019, the LC incidences were nearly 3.15 times higher in males than in females. LC cases and LC-associated deaths were mostly found among patients aged 65 to 69 years. The proportion of LC attributable to hepatitis B decreased over time, whereas the proportions of LC attributable to hepatitis C, alcohol use, and non-alcoholic steatohepatitis increased modestly from 1990 to 2019. The majority of LC-associated deaths could be traced to four risk factors: smoking (20%), drug use (13.6%), alcohol use (11.7%), and high body mass index (10.1%). Based on the Nordpred prediction, there will be a steady decline in the incidence (39.0%) and mortality (38.3%) of liver cancer over a 25-year period from 2020 to 2044.

Conclusion: The disease burden of liver cancer in China has declined over the past 30 years. However, it remains important to control liver cancer among high-risk populations, especially elderly males with obesity, alcohol use, tobacco use, and/or drug abuse.

Citing Articles

Global, regional and national burden of liver cancer 1990-2021: a systematic analysis of the global burden of disease study 2021.

Jiang Z, Zeng G, Dai H, Bian Y, Wang L, Cao W BMC Public Health. 2025; 25(1):931.

PMID: 40057711 PMC: 11890516. DOI: 10.1186/s12889-025-22026-6.

Temporal Trends in the Burden of Diabetes and Its Risk Factors Across the Western Pacific Region Between 1990 and 2044: A Systematic Analysis of the Global Burden of Disease Study 2019.

Liu X, Wu B, Lai Y, Zhang X, Li H, Qu F Diabetes Metab Res Rev. 2025; 41(2):e70036.

PMID: 39983069 PMC: 11845174. DOI: 10.1002/dmrr.70036.

Novel role of general transcript factor IIH subunit 2 (GTF2H2) in the development and sex disparity of hepatocellular carcinoma.

Li Y, OuYang Q, Chen Z, Zhou D, Li Z, Yang X Oncogene. 2025; .

PMID: 39972070 DOI: 10.1038/s41388-025-03301-7.

Global, regional and national burdens of Nasopharynx cancer in the adolescents and young adults from 1990 to 2019 and its predictions.

Huang G, Wang Y, Qin B, Zeng J, Tan H, Zhang D BMC Cancer. 2024; 24(1):720.

PMID: 38862937 PMC: 11167860. DOI: 10.1186/s12885-024-12480-7.

Metabolic risks remain a serious threat to cardiovascular disease: findings from the Global Burden of Disease Study 2019.

Li R, Shao J, Hu C, Xu T, Zhou J, Zhang J Intern Emerg Med. 2024; 19(5):1299-1312.

PMID: 38642311 DOI: 10.1007/s11739-024-03605-8.

References

. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390(10100):1345-1422. PMC: 5614451. DOI: 10.1016/S0140-6736(17)32366-8. View

Moller H, Fairley L, Coupland V, Okello C, Green M, Forman D . The future burden of cancer in England: incidence and numbers of new patients in 2020. Br J Cancer. 2007; 96(9):1484-8. PMC: 2360166. DOI: 10.1038/sj.bjc.6603746. View

. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396(10258):1223-1249. PMC: 7566194. DOI: 10.1016/S0140-6736(20)30752-2. View

Chen Y, Wang X, Wang J, Yan Z, Luo J . Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. Eur J Cancer. 2012; 48(14):2137-45. DOI: 10.1016/j.ejca.2012.02.063. View

Afshin A, Forouzanfar M, Reitsma M, Sur P, Estep K, Lee A . Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017; 377(1):13-27. PMC: 5477817. DOI: 10.1056/NEJMoa1614362. View

Li S, Chen H, Man J, Zhang T, Yin X, He Q . Changing trends in the disease burden of esophageal cancer in China from 1990 to 2017 and its predicted level in 25 years. Cancer Med. 2021; 10(5):1889-1899. PMC: 7940228. DOI: 10.1002/cam4.3775. View

Zeeneldin A, Eid Salem S, Darwish A, El-Gammal M, Hussein M, Saadeldin M . Untreated hepatocellular carcinoma in Egypt: outcome and prognostic factors. J Hepatocell Carcinoma. 2016; 2:3-9. PMC: 4918279. DOI: 10.2147/JHC.S73828. View

Pouget E, Hagan H, Des Jarlais D . Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment. Addiction. 2011; 107(6):1057-65. PMC: 3348401. DOI: 10.1111/j.1360-0443.2011.03765.x. View

Valery P, Laversanne M, Clark P, Petrick J, McGlynn K, Bray F . Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology. 2017; 67(2):600-611. PMC: 5832532. DOI: 10.1002/hep.29498. View

10.

Li G, Xu M, Yue T, Gu W, Tan L . Life-long passion for antiviral research and drug development: 80th birthday of Prof. Dr. Erik De Clercq. Biochem Pharmacol. 2021; 185:114485. PMC: 7895689. DOI: 10.1016/j.bcp.2021.114485. View

11.

Bailey J, Barnes E, Cox A . Approaches, Progress, and Challenges to Hepatitis C Vaccine Development. Gastroenterology. 2018; 156(2):418-430. PMC: 6340767. DOI: 10.1053/j.gastro.2018.08.060. View

12.

Liu Y, Zheng J, Hao J, Wang R, Liu X, Gu P . Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019. Cancer Med. 2022; 11(5):1310-1323. PMC: 8894698. DOI: 10.1002/cam4.4551. View

13.

Cui F, Shen L, Li L, Wang H, Wang F, Bi S . Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China. Emerg Infect Dis. 2017; 23(5):765-772. PMC: 5403029. DOI: 10.3201/eid2305.161477. View

14.

Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu M, Allen C . The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol. 2017; 3(12):1683-1691. PMC: 5824275. DOI: 10.1001/jamaoncol.2017.3055. View

15.

Campbell J, Garfein R, Thiede H, Hagan H, Ouellet L, Golub E . Convenience is the key to hepatitis A and B vaccination uptake among young adult injection drug users. Drug Alcohol Depend. 2007; 91 Suppl 1:S64-72. DOI: 10.1016/j.drugalcdep.2006.09.022. View

16.

de Martel C, Maucort-Boulch D, Plummer M, Franceschi S . World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology. 2015; 62(4):1190-200. PMC: 5019261. DOI: 10.1002/hep.27969. View

17.

Lee Y, Cohet C, Yang Y, Stayner L, Hashibe M, Straif K . Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer. Int J Epidemiol. 2009; 38(6):1497-511. DOI: 10.1093/ije/dyp280. View

18.

Miao M, Jing X, De Clercq E, Li G . Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy. Drug Des Devel Ther. 2020; 14:2759-2774. PMC: 7368560. DOI: 10.2147/DDDT.S254754. View

19.

Li G, De Clercq E . A medicinal chemist who reshaped the antiviral drug industry: John Charles Martin (1951-2021). Med Res Rev. 2021; 42(2):647-653. DOI: 10.1002/med.21858. View

20.

. Five insights from the Global Burden of Disease Study 2019. Lancet. 2020; 396(10258):1135-1159. PMC: 7116361. DOI: 10.1016/S0140-6736(20)31404-5. View